Macro and Microcirculatory Effects of the Combination of Norepinephrine and Octreotide for the Treatment of Cirrhotic Patients With Hemorrhagic Shock (HemodyNoOc)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Stéphanie Malaquin, Dr
- Phone Number: (33) 322087877
- Email: malaquin.stephanie@chu-amiens.fr
Study Contact Backup
- Name: Salah MATTOUG
- Phone Number: (33)322088370
- Email: mattoug.salah@chu-amiens.fr
Study Locations
-
-
-
Amiens, France, 80000
- CHU Amiens Picardie
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients more than 18 years old
- patient with liver cirrhosis
- patient with haemorrhagic shock due to variceal bleeding
- patient with an arterial blood pressure less than 65 mmHg despite
- patient able to express consent
- signed written informed consent form
- patient covered by national health insurance
Exclusion Criteria:
- patient less than 18 years old
- patient non covered by national health insurance
- pregnant or breast feeding patent
- known octreotide allergy
- cardiac arrest because of shock
- refused consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: octreotide (25 µg/hour) perfusion
octreotide (25 µg/hour) plus norepinephrine will be administered for patient with haemorrhagic shock after variceal bleeding during 2 to 5 days according recommendations and regular protocol in the medical unit
|
Patients admitted in intensive care unit after variceal hemorrhage treated with norepinephrine perfusion will received an additional octreotide perfusion during one hour.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline of microcirculatory flow index
Time Frame: one hour after octreotide perfusion
|
microcirculatory flow index will be measured with sidestream dark field handheld microscope.
Baseline is before octreotide perfusion.
Flow characteristics of the microvasculature will be quantified using the microcirculatory flow index (MFI) according to the recommendations from the consensus on microcirculatory imaging by De Backer et al.
This index will be calculated after the image will be divided into four quadrants, and the predominant type of flow (absent = 0, intermittent = 1, sluggish = 2, abnormal = 3, and hyperdynamic = 4) would be estimated in the vessels smaller than 25 μm by the operator.
The final MFI score is a value obtained from the average score of the four areas.
|
one hour after octreotide perfusion
|
|
Change from baseline of microcirculatory flow index
Time Frame: 2 hours after octreotide perfusion
|
microcirculatory flow index will be measured with sidestream dark field handheld microscope.
Baseline is before octreotide perfusion.
Flow characteristics of the microvasculature will be quantified using the microcirculatory flow index (MFI) according to the recommendations from the consensus on microcirculatory imaging by De Backer et al.
This index will be calculated after the image will be divided into four quadrants, and the predominant type of flow (absent = 0, intermittent = 1, sluggish = 2, abnormal = 3, and hyperdynamic = 4) would be estimated in the vessels smaller than 25 μm by the operator.
The final MFI score is a value obtained from the average score of the four areas.
|
2 hours after octreotide perfusion
|
|
Change from baseline of microcirculatory flow index
Time Frame: 6 hours after octreotide perfusion
|
microcirculatory flow index will be measured with sidestream dark field handheld microscope.
Baseline is before octreotide perfusion.
Flow characteristics of the microvasculature will be quantified using the microcirculatory flow index (MFI) according to the recommendations from the consensus on microcirculatory imaging by De Backer et al.
This index will be calculated after the image will be divided into four quadrants, and the predominant type of flow (absent = 0, intermittent = 1, sluggish = 2, abnormal = 3, and hyperdynamic = 4) would be estimated in the vessels smaller than 25 μm by the operator.
The final MFI score is a value obtained from the average score of the four areas.
|
6 hours after octreotide perfusion
|
|
Change from baseline of microcirculatory flow index
Time Frame: 12 hours after octreotide perfusion
|
microcirculatory flow index will be measured with sidestream dark field handheld microscope.
Baseline is before octreotide perfusion.
Flow characteristics of the microvasculature will be quantified using the microcirculatory flow index (MFI) according to the recommendations from the consensus on microcirculatory imaging by De Backer et al.
This index will be calculated after the image will be divided into four quadrants, and the predominant type of flow (absent = 0, intermittent = 1, sluggish = 2, abnormal = 3, and hyperdynamic = 4) would be estimated in the vessels smaller than 25 μm by the operator.
The final MFI score is a value obtained from the average score of the four areas.
|
12 hours after octreotide perfusion
|
|
Change from baseline of microcirculatory flow index
Time Frame: 24 hours after octreotide perfusion
|
microcirculatory flow index will be measured with sidestream dark field handheld microscope.
Baseline is before octreotide perfusion.
Flow characteristics of the microvasculature will be quantified using the microcirculatory flow index (MFI) according to the recommendations from the consensus on microcirculatory imaging by De Backer et al.
This index will be calculated after the image will be divided into four quadrants, and the predominant type of flow (absent = 0, intermittent = 1, sluggish = 2, abnormal = 3, and hyperdynamic = 4) would be estimated in the vessels smaller than 25 μm by the operator.
The final MFI score is a value obtained from the average score of the four areas.
|
24 hours after octreotide perfusion
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
percentage of perfused vessels
Time Frame: before and one hour after octreotide perfusion
|
percentage of perfused vessels will be measured with sidestream dark field handheld microscope
|
before and one hour after octreotide perfusion
|
|
percentage of perfused vessels
Time Frame: 2 hours after octreotide perfusion
|
percentage of perfused vessels will be measured with sidestream dark field handheld microscope
|
2 hours after octreotide perfusion
|
|
percentage of perfused vessels
Time Frame: 6 hours after octreotide perfusion
|
percentage of perfused vessels will be measured with sidestream dark field handheld microscope
|
6 hours after octreotide perfusion
|
|
percentage of perfused vessels
Time Frame: 12 hours after octreotide perfusion
|
percentage of perfused vessels will be measured with sidestream dark field handheld microscope
|
12 hours after octreotide perfusion
|
|
percentage of perfused vessels
Time Frame: 24 hours after octreotide perfusion
|
percentage of perfused vessels will be measured with sidestream dark field handheld microscope
|
24 hours after octreotide perfusion
|
|
functional capillary density
Time Frame: before and one hour after octreotide perfusion
|
functional capillary density will be measured with sidestream dark field handheld microscope
|
before and one hour after octreotide perfusion
|
|
functional capillary density
Time Frame: 2 hours after octreotide perfusion
|
functional capillary density will be measured with sidestream dark field handheld microscope
|
2 hours after octreotide perfusion
|
|
functional capillary density
Time Frame: 6 hours after octreotide perfusion
|
functional capillary density will be measured with sidestream dark field handheld microscope
|
6 hours after octreotide perfusion
|
|
functional capillary density
Time Frame: 12 hours after octreotide perfusion
|
functional capillary density will be measured with sidestream dark field handheld microscope
|
12 hours after octreotide perfusion
|
|
functional capillary density
Time Frame: 24 hours after octreotide perfusion
|
functional capillary density will be measured with sidestream dark field handheld microscope
|
24 hours after octreotide perfusion
|
|
Mean arterial pressure
Time Frame: before and one hour after octreotide perfusion
|
Mean arterial pressure
|
before and one hour after octreotide perfusion
|
|
Mean arterial pressure
Time Frame: 2 hours after octreotide perfusion
|
Mean arterial pressure
|
2 hours after octreotide perfusion
|
|
Mean arterial pressure
Time Frame: 6 hours after octreotide perfusion
|
Mean arterial pressure
|
6 hours after octreotide perfusion
|
|
Mean arterial pressure
Time Frame: 12 hours after octreotide perfusion
|
Mean arterial pressure
|
12 hours after octreotide perfusion
|
|
Mean arterial pressure
Time Frame: 24 hours after octreotide perfusion
|
Mean arterial pressure
|
24 hours after octreotide perfusion
|
|
heart rate
Time Frame: before and one hour after octreotide perfusion
|
heart rate
|
before and one hour after octreotide perfusion
|
|
heart rate
Time Frame: 2 hours after octreotide perfusion
|
heart rate
|
2 hours after octreotide perfusion
|
|
heart rate
Time Frame: 6 hours after octreotide perfusion
|
heart rate
|
6 hours after octreotide perfusion
|
|
heart rate
Time Frame: 12 hours after octreotide perfusion
|
heart rate
|
12 hours after octreotide perfusion
|
|
heart rate
Time Frame: 24 hours after octreotide perfusion
|
heart rate
|
24 hours after octreotide perfusion
|
|
ejection fraction
Time Frame: before and one hour after octreotide perfusion
|
ejection fraction
|
before and one hour after octreotide perfusion
|
|
ejection fraction
Time Frame: 2 hours after octreotide perfusion
|
ejection fraction
|
2 hours after octreotide perfusion
|
|
ejection fraction
Time Frame: 6 hours after octreotide perfusion
|
ejection fraction
|
6 hours after octreotide perfusion
|
|
ejection fraction
Time Frame: 12 hours after octreotide perfusion
|
ejection fraction
|
12 hours after octreotide perfusion
|
|
ejection fraction
Time Frame: 24 hours after octreotide perfusion
|
ejection fraction
|
24 hours after octreotide perfusion
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PI2018_843_0016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.